glp-1 compounding news november 2025 Pharmacovigilance Assessment of Compounded Receptor Agonists: Insights From the FDA Adverse Event Reporting System Republican Administration Maintains Exclusivity Stance

It is prescribed for individuals with a body mass index (BMI) of 30 or greater or those with a BMI between 27 and 30 who have weight-related health conditions, such as high blood pressure or type 2 diabetes Ozempic (Semaglutide) , while effective for weight loss in some clinical trials, is approved in Singapore for diabetes management, not as a dedicated weight loss treatment

Gibbons, R., Hur, K., Lavigne, J., Wang, J

a multi-disciplinary expert consensus

There are several mechanisms involved in the development of steroid-induced hyperglycemia (SIH) and steroid-induced diabetes

Constipation is a common side effect of GLP-1 medications like Ozempic and Wegovy

Weight loss during the first week is highly variable and often minimal, as starting doses are intentionally low